International Entrepreneurs Revolutionize the Retail Industry With Their Sustainable Marketplace Staiy
BERLIN, GERMANY / ACCESSWIRE / December 13, 2021 / Staiy is a unique, sustainable, and…
BERLIN, GERMANY / ACCESSWIRE / December 13, 2021 / Staiy is a unique, sustainable, and…
TORONTO, ON and LONDON, UK / ACCESSWIRE / December 13, 2021 / Retained executive search…
VILNIUS, LITHUANIA / ACCESSWIRE / December 13, 2021 / If you are even remotely aware…
ANAHEIM, CA / ACCESSWIRE / December 13, 2021 / SPI Energy Co., Ltd. (“SPI Energy”…
LONDON, UK / ACCESSWIRE / December 13, 2021 / The creators of Ethereum-based NFT token…
LONDON, UK / ACCESSWIRE / December 13, 2021 / Love Hemp Group PLC (AQSE:LIFE) (OTCQB:WRHLF),…
FT MYERS, FL / ACCESSWIRE / December 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading…
ÖSTERREICH, AUSTRIA / ACCESSWIRE / December 13, 2021 / SolidETH is this years paradigm shifting…
New ‘Talking Seniors’ podcast episode features matrimonial attorney John A. Pappalardo of Farber, Pappalardo &…
Pedri wins the Golden Boy Award 2021 – and is already making arrangements for the…
Media Release Copenhagen, Denmark, December 13, 2021 The European Commission has granted Janssen-Cilag International NV…
The partnership will develop new biotech solutions aimed at carbon capture through enzymes. COPENHAGEN, DENMARK…
LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a…
Press Release Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and…
At the 2021 American Society of Hematology (ASH) Annual Meeting NANTES, France, Dec. 13, 2021…
Next-generation sequencing (NGS) enables a better understanding of genetic mechanisms linked to specific diseases and…
This announcement contains inside information for the purposes of Article 7 of the Market Abuse…
People with moderate or mild haemophilia A have significant unmet clinical needs, as this population…
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland…
Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe…